Alyeska Investment Group Portfolio holdings
AUM
$28.2B
1-Year Return
38.86%
This Quarter Return
-2.3%
1 Year Return
+38.86%
3 Year Return
+101.95%
5 Year Return
+160.93%
10 Year Return
+424.53%
AUM
$25B
AUM Growth
-$1.57B
(-5.9%)
Cap. Flow
-$922M
Cap. Flow
% of AUM
-3.69%
Top 10 Holdings %
Top 10 Hldgs %
22.22%
Holding
695
New
157
Increased
139
Reduced
161
Closed
203
Top Buys
| 1 |
Amazon
AMZN
|
$494M |
| 2 |
Microsoft
MSFT
|
$376M |
| 3 |
Salesforce
CRM
|
$265M |
| 4 |
Electronic Arts
EA
|
$225M |
| 5 |
AT&T
T
|
$217M |
Top Sells
| 1 |
iShares Core S&P 500 ETF
IVV
|
$833M |
| 2 |
Alibaba
BABA
|
$479M |
| 3 |
Meta Platforms (Facebook)
META
|
$398M |
| 4 |
Boeing
BA
|
$328M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
$321M |
Sector Composition
| 1 | Technology | 21.48% |
| 2 | Consumer Discretionary | 12.61% |
| 3 | Healthcare | 10.38% |
| 4 | Industrials | 10.15% |
| 5 | Real Estate | 8.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
401
Biohaven
BHVN
$1.68B
| $2.56M | 0.01% |
106,351
| – | – |
|
402
Eli Lilly
LLY
$652B
| $2.52M | 0.01% |
+3,055
| New | +$2.52M |
|
403
Toll Brothers
TOL
$14.2B
| $2.51M | 0.01% |
23,742
-17,367
| -42% | -$1.83M |
|
404
Oculis Holding
OCS
$901M
| $2.5M | 0.01% |
+131,332
| New | +$2.5M |
|
|
KMTS
405
Kestra Medical Technologies, Ltd. Common Stock
KMTS
$873M
| $2.49M | 0.01% |
+100,000
| New | +$2.49M |
|
406
Arbe Robotics
ARBE
$140M
| $2.41M | 0.01% |
2,339,726
-1,760,693
| -43% | -$1.81M |
|
|
AVR
407
Anteris Technologies Global Corp. Common Stock
AVR
$150M
| $2M | 0.01% |
550,000
| – | – |
|
408
Pentair
PNR
$18.1B
| $1.99M | 0.01% |
+22,783
| New | +$1.99M |
|
409
Denison Mines
DNN
$2.11B
| $1.95M | 0.01% |
1,500,000
-18,409,605
| -92% | -$23.9M |
|
|
SION
410
Sionna Therapeutics, Inc. Common Stock
SION
$1.06B
| $1.95M | 0.01% |
+186,222
| New | +$1.95M |
|
411
Beyond Air
XAIR
$11.5M
| $1.95M | 0.01% |
357,110
| – | – |
|
412
EyePoint Pharmaceuticals
EYPT
$966M
| $1.9M | 0.01% |
351,348
| – | – |
|
413
Endava
DAVA
$553M
| $1.89M | 0.01% |
96,709
-1,709,335
| -95% | -$33.3M |
|
414
Modular Medical
MODD
$39.6M
| $1.86M | 0.01% |
1,708,332
+1,041,666
| +156% | +$1.14M |
|
415
Tourmaline Bio
TRML
$687M
| $1.75M | 0.01% |
115,053
| – | – |
|
|
ACOG
416
Alpha Cognition Inc. Common Stock
ACOG
$144M
| $1.71M | 0.01% |
337,466
-62,534
| -16% | -$316K |
|
417
KB Home
KBH
$4.63B
| $1.69M | 0.01% |
+29,135
| New | +$1.69M |
|
|
RGLS
418
DELISTED
Regulus Therapeutics
RGLS
| $1.64M | 0.01% |
937,500
-100,000
| -10% | -$175K |
|
419
Health Catalyst
HCAT
$238M
| $1.58M | 0.01% |
349,194
-1,670,186
| -83% | -$7.57M |
|
|
SLRN
420
DELISTED
ACELYRIN
SLRN
| $1.52M | 0.01% |
615,878
-900,000
| -59% | -$2.22M |
|
421
Applied Therapeutics
APLT
$68.2M
| $1.52M | 0.01% |
3,107,497
+400,000
| +15% | +$196K |
|
422
P3 Health Partners
PIII
$28.7M
| $1.48M | 0.01% |
180,907
-57,212
| -24% | -$469K |
|
|
CBLL
423
CeriBell, Inc. Common Stock
CBLL
$433M
| $1.44M | 0.01% |
75,000
-50,000
| -40% | -$961K |
|
|
MAZE
424
Maze Therapeutics, Inc. Common Stock
MAZE
$696M
| $1.38M | 0.01% |
+125,000
| New | +$1.38M |
|
425
Novartis
NVS
$251B
| $1.31M | 0.01% |
+11,722
| New | +$1.31M |
|